Matrixyl (Pal-KTTKS)
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Matrixyl (Pal-KTTKS) is listed as beauty / topical collagen stimulator.
- •Wrinkles
- •Dermal collagen support
Regulatory status: Cosmetic ingredient (global).
Structure & Properties
Compound: Matrixyl (Pal-KTTKS); also known as Palmitoyl Pentapeptide-4, Pal-KTTKS.
Pharmacologic class: Beauty / Topical Collagen Stimulator.
Known delivery routes: Topical.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Lipidated pentapeptide derived from procollagen I C-terminus — signals fibroblasts to upregulate collagen I, III, and fibronectin synthesis.
- •Reduced fine lines
- •Improved skin density
- •Well tolerated
Human Research
Evidence grade: Clinical RCT (Limited)
Clinical RCT (Limited). Multiple split-face cosmetic RCTs.
Laboratory Research
Multiple split-face cosmetic RCTs
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Topical, 1–2× daily (AM and/or PM). Layer under moisturizer. Avoid same-application vitamin C or strong acids.
Potential interactions and combinations to avoid
- •Concurrent same-time strong acids/retinoids — separate by 12 hrs
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Mild irritation (rare)
- •Slow onset (8–12 weeks)
Contraindications
- •Active dermatitis on application site
- •Broken, infected, sunburned, or actively inflamed skin
- •Concurrent prescription retinoid, chemical peel, or laser resurfacing without dermatologic guidance
- •Known copper sensitivity or Wilson's disease (copper-carrier peptides)
- •Eczema, rosacea, or perioral dermatitis in active flare
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 3–5% in topical formulation
Frequency: 1–2× daily
Cycling: Continuous topical use.
Topical
Cosmetic anti-aging.
Serum (3–5% Matrixyl 3000 or Synthe'6). Apply to clean skin AM and PM under moisturizer.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Argireline (AM), GHK-Cu (opposite time of day)
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Matrixyl (Pal-KTTKS)?
In plain words
Matrixyl is a short chain of five amino acids, the building blocks of proteins, linked to a fatty acid and used in skin-care products. It can signal skin cells to make more collagen and other proteins that help support skin structure. Researchers study it for reducing wrinkles and supporting skin collagen, but human trial evidence is limited. Mild skin irritation can occur.
Technical definition
Matrixyl (Pal-KTTKS), also called palmitoyl pentapeptide-4, is a lipidated signaling peptide composed of palmitic acid linked to the five-amino-acid sequence lysine–threonine–threonine–lysine–serine, derived from the C-terminal region of type I procollagen. It signals dermal fibroblasts to increase synthesis of collagen types I and III and fibronectin, although a specific receptor has not been firmly established. It is used internationally as a cosmetic ingredient and is not an FDA-approved drug.
Function
Dosing
Recommended Time of Day
Topical, morning and evening skincare routine.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Face / neck (topical) — Clean dry skin, AM and PM, before moisturizer.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous topical use.
Timing & Interactions
- ·Concurrent same-time strong acids/retinoids — separate by 12 hrs
- ·Argireline (AM), GHK-Cu (opposite time of day)
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Matrixyl (Pal-KTTKS) and sync them to Vial Lab.
Benefits
- ·Reduced fine lines
- ·Improved skin density
- ·Well tolerated
Risks
- ·Mild irritation (rare)
- ·Slow onset (8–12 weeks)
Contraindications
- ·Active dermatitis on application site
- ·Broken, infected, sunburned, or actively inflamed skin
- ·Concurrent prescription retinoid, chemical peel, or laser resurfacing without dermatologic guidance
- ·Known copper sensitivity or Wilson's disease (copper-carrier peptides)
- ·Eczema, rosacea, or perioral dermatitis in active flare
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Cosmetic ingredient (global)
Veterinary Use (Pets)
No established veterinary protocol for Matrixyl (Pal-KTTKS). Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.